The use of tocilizumab in PAN has not been approved by the United States Food and Drug Administration (FDA), but the blockage of IL-6 with tocilizumab has been used effectively to treat other forms of vasculitis [19, 20]. The gene discussed is IL6; the disease is vasculitis.